ANGLE PLC’s dual DNA workflow breakthrough with Illumina

Proactive - Interviews for investors

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) Chief Executive Andrew Newland talked with Proactive's Stephen Gunnion about the company’s recent breakthrough in dual ctDNA and CTC DNA analysis on the Illumina platform. The six-month project overcame technical hurdles to achieve an end-to-end solution using Illumina’s specialist lung cancer DNA kit, demonstrating its potential impact in a 27-patient study. Newland highlighted that ANGLE’s Parsortix system identified actionable DNA variants in circulating tumor cells (CTCs) that were not present in ctDNA samples. This advancement underscores the importance of analysing intact cancer cells rather than focusing solely on fragmented DNA. He also noted that Illumina has allocated its upcoming European Association of Cancer Research conference webinar to ANGLE’s findings, marking the start of a co-marketing initiative. On the relevance of artificial intelligence (AI), Newland explained how it is used in analysing proteins on cells and molecular signatures, emphasising that the best possible sample, like Parsortix-based ones, is key to maximising the impact of AI and sequencing in liquid biopsies. For more insights, visit Proactive’s YouTube channel, and don’t forget to like, subscribe, and enable notifications to stay updated." #ANGLEPLC #LiquidBiopsy #CancerResearch #IlluminaCollaboration #Parsortix #CTCDNA #LungCancer #ArtificialIntelligence #MedicalBreakthrough #BiotechInnovation